This federal contract award is for a Small Business Innovation Research (SBIR) Phase I effort by Altrazeal Life Sciences Inc., doing business as Uluru, to develop an "Innovative Adaptive Drug Delivery System Enhanced Neuroprotection Repair Traumatic Brain Injuries from Penetrating Trauma Open Skull Fractures in Low Resource Envir." The $249,999.96 firm fixed-price contract was awarded by the Defense Health Agency (DHA) on October 7, 2024 and runs through May 6, 2025. The research is related to DHA's SBIR Topic DHA242-003, which focuses on wound care and drug delivery solutions to support treatment of traumatic brain injuries. Altrazeal, a medical equipment manufacturer, has also received a $3.8 million grant from DHA for an innovative wound management solution and serves as a subcontractor on a grant evaluating components to improve chronic wound healing.
Generated 1/6/25, 12:32 PM